Pharming Group N.V. announces that the US Food and Drug Administration has accepted for priority review its New Drug Application for leniolisib, an oral, selective phosphoinositide 3-kinase delta inhibitor, to treat the rare primary immunodeficiency activated phosphoinositide 3-kinase delta syndrome in adults and adolescents 12 years of age and older in the US.
September 28, 2022
· 7 min read